The shift in body composition that follows menopause is not simply a matter of weight gain. It is a specific and metabolically dangerous remodelling: subcutaneous fat decreases in relative terms while visceral adipose tissue — the fat surrounding the liver, pancreas and visceral organs — rises sharply. In women who transition through menopause in their late 40s and 50s, researchers have documented a 15-20% increase in VAT independent of total body weight change. This happens because two systems that had been jointly suppressing visceral fat accumulation throughout reproductive life — oestrogen signalling and pulsatile GH secretion — both collapse at roughly the same time.
Tesamorelin enters this picture as a GHRH analog that restores the pulsatile GH signal without directly suppressing oestrogen. For investigators studying midlife metabolic remodelling, it is one of the few research tools with randomised controlled trial data on visceral fat as a primary endpoint. If you are running this line of research in the UAE and need HPLC-verified vials with documented lot-COA, REVIVE LAB UAE supplies tesamorelin Dubai 24h delivery on 5 mg and 10 mg vials to every emirate.
To understand why tesamorelin is a rational candidate for menopause-related visceral fat research, investigators need to understand both legs of the mechanism:
The implication for menopausal visceral fat research is that correcting oestrogen alone may not resolve the GH-axis component. These are two mechanistically distinct inputs, and investigators studying the GH axis specifically have gravitated toward tesamorelin as the GHRH-class molecule with the strongest controlled-trial evidence base.
The landmark randomised controlled trial published by Falutz and colleagues in the New England Journal of Medicine (2007) enrolled 412 subjects with elevated visceral fat — the largest tesamorelin VAT trial to that point. Over 26 weeks, the tesamorelin 2 mg/day subcutaneous arm showed a 15-18% reduction in VAT measured by CT versus placebo. Critically, this was not a weight-loss effect — total body weight did not change significantly between arms. The VAT reduction was depot-selective. Investigators also observed an approximately 50% rise in IGF-1, consistent with restored pulsatile GH output acting on hepatic GH receptors.
The 2010 26-week extension trial confirmed durability: subjects who continued tesamorelin maintained VAT reductions, while subjects who switched from tesamorelin to placebo experienced partial VAT reaccumulation over the extension period. This rebound pattern is methodologically important for investigators designing research protocols — it suggests the VAT signal is dependent on continued GHRH stimulation rather than a permanent structural reset. For the menopause research context, this speaks to the question of whether the GH axis requires ongoing support or whether short-course intervention produces lasting depot remodelling.
Stanley and colleagues at Massachusetts General Hospital published the JAMA 2014 trial examining tesamorelin in subjects with visceral fat accumulation and non-alcoholic fatty liver disease (NAFLD). Over 12 months, the tesamorelin arm showed a 32% reduction in liver fat measured by magnetic resonance spectroscopy versus placebo. This ectopic fat endpoint is particularly relevant for midlife menopausal research, since post-menopausal women show significantly elevated rates of NAFLD relative to pre-menopausal women — likely driven by the same VAT-GH axis mechanisms described above.
The 2019 Lancet HIV publication extended the NAFLD finding over 12 months with a randomised, double-blind, multicentre design. The liver-fat reduction persisted to 12 months, and secondary metabolic markers — including triglycerides and adiponectin — moved in favourable directions in the tesamorelin arm. For investigators building a research framework around menopausal metabolic remodelling, the 12-month data provides a timeframe reference for how long sustained GH axis restoration needs to run before organ-level effects stabilise.
The GH axis in peri- and post-menopausal women has a distinct pharmacodynamic profile compared to the populations studied by Falutz and Stanley — primarily men with HIV-associated lipodystrophy. Investigators designing menopause-specific research protocols typically need to account for several differences:
REVIVE LAB UAE supplies HPLC-verified tesamorelin to researchers across the UAE who are running this line of work — the vial specifications, lot documentation and cold-chain dispatch are designed for investigators who need research-grade material, not variable-quality generic stock. For researchers in Dubai, Abu Dhabi, Sharjah and beyond, this is the fastest path to tesamorelin in stock UAE with same-day cold-chain dispatch.
REVIVE LAB UAE stocks tesamorelin exclusively in the vial sizes used in the peer-reviewed literature — 5 mg and 10 mg lyophilized vials. The 1 mg or 2 mg/day research-context dosing referenced in the Falutz and Stanley protocols maps cleanly onto these formats.
| Vial Size | BAC Water | Concentration | Research-Context Daily Volume (1 mg/day) | Research-Context Daily Volume (2 mg/day) |
|---|---|---|---|---|
| Tesamorelin 5 mg | 1 mL | 5 mg/mL | 0.2 mL (200 mcL) | 0.4 mL (400 mcL) |
| Tesamorelin 5 mg | 2 mL | 2.5 mg/mL | 0.4 mL | 0.8 mL |
| Tesamorelin 10 mg | 2 mL | 5 mg/mL | 0.2 mL | 0.4 mL |
| Tesamorelin 10 mg | 4 mL | 2.5 mg/mL | 0.4 mL | 0.8 mL |
Reconstitution follows standard lyophilized peptide technique: add bacteriostatic water slowly down the inside wall of the vial, do not inject directly onto the lyo cake, swirl gently without shaking. Reconstituted vials should be stored at 2-8°C and used within the stability window documented by the manufacturer. REVIVE LAB UAE vials are shipped lyophilized in cold-chain insulated packaging that maintains 2-8°C through UAE inter-emirate transit.
Investigators running tesamorelin VAT research protocols in the menopause context typically monitor a set of primary and secondary endpoints that reflect both the mechanism and the downstream metabolic consequences of VAT reduction. The Falutz and Stanley trials provide the methodological benchmark:
| Endpoint | Measurement Method | Direction in Published Trials |
|---|---|---|
| Visceral adipose tissue (VAT) | CT cross-section at L4 (cm²) | -15 to -18% vs. placebo (Falutz 2007, 2010) |
| IGF-1 | Serum (ng/mL) | ~+50% vs. placebo (Falutz 2007) |
| Liver fat fraction | MRS or MRI-PDFF (%) | -32% vs. placebo (Stanley 2014) |
| Fasting triglycerides | Serum (mmol/L) | Favourable trend (Stanley 2019) |
| Adiponectin | Serum (mcg/mL) | Favourable trend (Stanley 2019) |
| Trunk-to-limb fat ratio | DEXA | Improved in treated arm (Falutz 2010) |
Investigators adding oestrogen-axis markers (E2, FSH, SHBG) to the panel can explore interaction effects between the GHRH restoration and the menopausal hormonal environment — a methodological layer not covered in the original Falutz and Stanley trials but increasingly relevant to research designs targeting post-menopausal cardiometabolic risk.
Investigators based in the UAE do not need to navigate international freight or variable cold-chain from overseas suppliers. REVIVE LAB UAE runs same-day cold-chain dispatch out of Dubai with refrigerated courier coverage to every emirate. Whether your research facility is in Dubai Marina, Business Bay, DIFC, JVC, JBR, Jumeirah, Palm Jumeirah, Downtown, Emirates Hills or Arabian Ranches — same-day dispatch applies.
| Emirate / City | Delivery Window | Cash on Delivery | Cold-Chain Packaging |
|---|---|---|---|
| Dubai (Marina, JBR, Business Bay, JVC, DIFC, Downtown, Palm, Jumeirah) | Same-day, 4-8 hours | Yes | Yes |
| Abu Dhabi (Corniche, Yas, Saadiyat, Reem) | Next-day, 18-24 hours | Yes | Yes |
| Sharjah | Same-day / next-day, 8-18 hours | Yes | Yes |
| Ajman | Next-day, 18-24 hours | Yes | Yes |
| Ras Al Khaimah (RAK) | Next-day, 18-24 hours | Yes | Yes |
| Fujairah | Next-day, 24 hours | Yes | Yes |
| Umm Al Quwain (UAQ) | Next-day, 18-24 hours | Yes | Yes |
| Al Ain | Next-day, 24 hours | Yes | Yes |
A researcher in Dubai ordering before 2pm typically has HPLC-verified cold-pack tesamorelin vials in hand by evening. This is what tesamorelin same day Dubai actually means when the supplier is genuinely Dubai-based rather than relabelling offshore stock. For investigators in Abu Dhabi, Sharjah, RAK or Fujairah, next-day tesamorelin 24h delivery is the standard dispatch window — not an upgraded tier.
REVIVE LAB UAE is a Dubai-based peptides UAE supplier — not a freight-forwarder or a reseller operating on another company's inventory. Every tesamorelin batch is HPLC-tested to ≥99% purity with lot-COA available on request. Vials are shipped in validated cold-chain insulated packaging that maintains 2-8°C through UAE summer ambient conditions. Tesamorelin 5 mg and 10 mg are in stock in Dubai now, dispatched same-day on weekdays with discreet, plain outer cartons — cash on delivery Dubai is standard, not an exception.
For investigators running broader peptide research stacks alongside tesamorelin — including Retatrutide for metabolic endpoint comparison, GHK-Cu for tissue-level endpoints, BPC-157, TB-500, Semax or NAD+ — the full REVIVE LAB UAE peptides UAE catalogue covers these in parallel. The point of REVIVE LAB UAE is straightforward: peptides UAE with the cold-chain, purity documentation and delivery speed that makes UAE-based research operationally viable, not an import logistics problem.
Yes. REVIVE LAB UAE stocks HPLC-verified tesamorelin 5 mg and 10 mg vials for research use across all seven emirates. Investigators can order tesamorelin Dubai with same-day delivery or buy tesamorelin UAE with 24h delivery to Abu Dhabi, Sharjah, RAK and Fujairah. Cash on delivery is available. All vials ship cold-chain with lot-COA documentation confirming ≥99% purity.
REVIVE LAB UAE carries tesamorelin 5 mg and 10 mg lyophilized vials — reflecting the exact formats used in the Falutz and Stanley published trial protocols. Research-context dosing referenced in the peer-reviewed literature is 1 mg/day to 2 mg/day administered subcutaneously. Investigators should refer to Falutz et al. 2007 (NEJM) and Stanley et al. 2014 (JAMA) for complete protocol methodology and monitoring frameworks.
Orders placed before the daily cut-off are dispatched same-day within Dubai — researchers in Dubai Marina, JBR, Business Bay, JVC, Jumeirah, DIFC, Palm Jumeirah, Downtown, Emirates Hills and Arabian Ranches typically receive vials within 4-8 hours. All other emirates receive tesamorelin 24h delivery. Cash on delivery Dubai is standard across the UAE, with discreet unbranded outer packaging on every shipment as default — not an optional upgrade.